BASIC AND CLINICAL STUDIES ON ME 1207 IN UROLOGY
スポンサーリンク
概要
- 論文の詳細を見る
We studied ME 1207, a new oral antimicrobial agent, to determine its antibacterial activity, absorption and excretion, clinical efficacy and side effects.<BR>1) The antibacterial activity of ME 1206 against <I>Staphylococcus aureus</I> and <I>Staphylococcus epidermidis</I> was superior to those of cefixime and cefaclor; against <I>Escherichia coli, Serratia marcescens</I> and <I>Klebsiella pneumoniae</I> it was similar to that of cefixime and clearly superior to that of cefaclor but these three agents showed low antibacterial activity against <I>Enterococcus faecalis</I> and <I>Pseudomonas aeruginosa</I>.<BR>2) ME 1207 (200mg) was administered to four healthy male volunteers. Serum levels reached a maximum of 2.57±0.97μg/ml lh after administration under fasting conditions and it reached 2.82±0.48μg/ml at 2h when given after meals. The urinary recovery rates within 24 h were 18.34±1.52% under fasting conditions and 21.55±3.99% when given after meals.<BR>3) Nineteen patients with complicated urinary tract infections were treated with ME 1207. In 10 of 14 cases the drug was effective according to the criteria of the Japanese UTI Committee.<BR>4) No side effects were observed in any of the cases, and clinical laboratory tests showed no abnormalities.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.